

- wherein R^2 represents hydrogen or C_{1-4} alkyl group;

R^3 represents hydrogen, halogen, CF_3, CN or C_{1-4} alkyl; and

R^4 represents hydrogen, halogen or C_{1-4} alkyl;

X represents a C_2 aliphatic hydrocarbon bridge optionally containing a double bond or a triple bond or a heteroatom selected from O and S, or $-CH(CH_2)CH-$;

Y represents hydrogen, halogen, C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} hydroxyalkyl;

Z represents a C_{1-4} aliphatic hydrocarbon bridge optionally containing one double bond, and/or one or more heteroatom selected from O, S, N and $N(CH_3)$ or represents a C_{2-4} aliphatic hydrocarbon bridge fused with a C_{3-6} cycloalkyl ring optionally containing one or more double bond or with a phenyl ring or represents a C_{1-4} aliphatic hydrocarbon bridge substituted with a spiro C_{3-6} cycloalkyl ring optionally containing one or more double bond;

or a salt thereof.

~~21. Use of one or more compounds according to any of claims 1 to 13 in the manufacture of a medicament for treating or preventing a CXCR3 receptor mediated disease or disorder, wherein the CXCR3 receptor mediated disease or is selected from the group consisting of COPD, psoriasis, graft/transplant rejection, ophthalmological disease, celiac disease, inflammatory bowel disease (IBD), type 1 diabetes, myasthenia gravis (MG), multiple sclerosis (MS) and other neuroinflammatory diseases, lupus, rheumatoid arthritis (RA) or lichen planus.~~